Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Selinexor in Diabetic Foot Ulcers
NCT02367690Phase 2Withdrawn
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of selinexor in diabetic foot ulcer (DFU) (3 cohorts), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Local Skin Reactions at 84 days. Planned start Jan 2015; status: withdrawn.
02
Drugs
selinexor
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02367690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367690.